Ισλανδία - Ισλανδικά - LYFJASTOFNUN (Icelandic Medicines Agency)

alvogen ehf. - allopurinolum inn - tafla - 100 mg

Ισλανδία - Ισλανδικά - LYFJASTOFNUN (Icelandic Medicines Agency)

alvogen ehf. - allopurinolum inn - tafla - 300 mg

Ισλανδία - Ισλανδικά - LYFJASTOFNUN (Icelandic Medicines Agency)

orion corporation - methotrexatum inn - tafla - 2,5 mg

Ευρωπαϊκή Ένωση - Ισλανδικά - EMA (European Medicines Agency)

viatris limited - tadalafil - háþrýstingur, lungnabólga - Þvaglát - talmanco er ætlað í fullorðnir fyrir meðferð lungum slagæð háan blóðþrýsting (pah) flokkast sem hagnýtur ii og iii, til að bæta æfing getu. verkun hefur verið sýnd í sjálfvakta pah (ipah) og í pah í tengslum við krabbameinsvaldandi sjúkdóma.

Ισλανδία - Ισλανδικά - LYFJASTOFNUN (Icelandic Medicines Agency)

krka, d.d., novo mesto - clarithromycinum inn - filmuhúðuð tafla - 250 mg

Ισλανδία - Ισλανδικά - LYFJASTOFNUN (Icelandic Medicines Agency)

krka, d.d., novo mesto - clarithromycinum inn - filmuhúðuð tafla - 500 mg

Ισλανδία - Ισλανδικά - LYFJASTOFNUN (Icelandic Medicines Agency)

alvogen ehf. - clarithromycinum inn - filmuhúðuð tafla - 500 mg

Ευρωπαϊκή Ένωση - Ισλανδικά - EMA (European Medicines Agency)

astrazeneca ab - acalabrutinib - kyrningahvítblæði, eitilfrumnafæð, langvarandi, b-frumur - antineoplastic agents, protein kinase inhibitors, - calquence as monotherapy or in combination with obinutuzumab is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (cll). calquence as monotherapy is indicated for the treatment of adult patients with chronic lymphocytic leukaemia (cll) who have received at least one prior therapy.

Ισλανδία - Ισλανδικά - LYFJASTOFNUN (Icelandic Medicines Agency)

krka sverige ab - lansoprazolum inn - magasýruþolið hart hylki - 30 mg

Ισλανδία - Ισλανδικά - LYFJASTOFNUN (Icelandic Medicines Agency)

krka sverige ab - lansoprazolum inn - magasýruþolið hart hylki - 15 mg